dc.contributor.author |
Mittal, Anshumali |
|
dc.contributor.author |
Khattri, Arun |
|
dc.contributor.author |
Verma, Vikash |
|
dc.date.accessioned |
2023-04-25T05:13:15Z |
|
dc.date.available |
2023-04-25T05:13:15Z |
|
dc.date.issued |
2022-02 |
|
dc.identifier.issn |
15537366 |
|
dc.identifier.uri |
http://localhost:8080/xmlui/handle/123456789/2238 |
|
dc.description |
This paper is submitted by the author of IIT (BHU), Varanasi, India |
en_US |
dc.description.abstract |
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)virus is continuously evolving, and this poses a major threat to antibody therapies and currently authorized Coronavirus Disease 2019 (COVID-19) vaccines. It is therefore of utmost importance to investigate and predict the putative mutations on the spike protein that confer immune evasion. Antibodies are key components of the human immune system's response to SARSCoV- 2, and the spike protein is a prime target of neutralizing antibodies (nAbs) as it plays critical roles in host cell recognition, fusion, and virus entry. The potency of therapeutic antibodies and vaccines partly depends on how readily the virus can escape neutralization. Recent structural and functional studies have mapped the epitope landscape of nAbs on the spike protein, which illustrates the footprints of several nAbs and the site of escape mutations. In this review, we discuss (1) the emerging SARS-CoV-2 variants; (2) the structural basis for antibody-mediated neutralization of SARS-CoV-2 and nAb classification; and (3) identification of the RBD escape mutations for several antibodies that resist antibody binding and neutralization. These escape maps are a valuable tool to predict SARS-CoV-2 fitness, and in conjunction with the structures of the spike-nAb complex, they can be utilized to facilitate the rational design of escape-resistant antibody therapeutics and vaccines. |
en_US |
dc.language.iso |
en_US |
en_US |
dc.publisher |
Public Library of Science |
en_US |
dc.relation.ispartofseries |
PLoS Pathogens;Volume 18, Issue 2 |
|
dc.subject |
Coronavirus spike glycoprotein |
en_US |
dc.subject |
Antigenic Variation |
en_US |
dc.subject |
Antibodies, Viral |
en_US |
dc.subject |
Antibodies |
en_US |
dc.subject |
COVID-19 |
en_US |
dc.subject |
COVID-19 Vaccines |
en_US |
dc.subject |
Mutation |
en_US |
dc.subject |
Spike Glycoprotein |
en_US |
dc.subject |
Antibodies, Neutralizing; Antibodies, Viral; Antigenic Variation; COVID-19; COVID-19 Vaccines; Epitopes; Humans; Immune Evasion; Models, Structural; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus |
en_US |
dc.title |
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants |
en_US |
dc.type |
Article |
en_US |